<sup>225</sup>Aс-PSMA-617 therapy in metastatic castration-resistant prostate cancer
177Lu-PSMA-617 is a new therapy option for PSMA-positive metastatic castrate-resistant metastatic prostate cancer (mCRPC) with proven efficacy. 225Ac-PCMA-617 is an alpha emitter, making this drug potentially more powerful. Despite the active use of 225Ac-PSMA-617 worldwide, no randomized phase III...
Saved in:
| Main Authors: | T. Yu. Kochetova, V. V. Krylov, S. A. Ivanov, A. D. Kaprin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2025-01-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/3360 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of <sup>177</sup>Lu-PSMA-617 Therapy in mCRPC Patients with Liver Metastases: Insights into Survival Outcomes and Predictors of Response
by: Ebuzer Kalender, et al.
Published: (2025-02-01) -
Actinium-225-PSMA-617 treatment in a patient with advanced prostate cancer causes secondary myelofibrosis: a case report and literature review
by: Ziye Wang, et al.
Published: (2025-07-01) -
Improvement of End-of-Synthesis Radiochemical Purity of <sup>177</sup>Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization
by: Anton Larenkov, et al.
Published: (2024-11-01) -
Comparison of ZnS(Ag) Scintillator and Proportional Counter Tube for Alpha Detection in Thin-Layer Chromatography
by: Marc Pretze, et al.
Published: (2024-12-01) -
Theranostics Nuclear Medicine in Prostate Cancer
by: Helena Lima, et al.
Published: (2024-11-01)